prednisone + chlorpropamide + methotrexate + doxorubicin + streptozocin + hydroxyurea

This is a combination regimen comprising six distinct drugs: **prednisone** (a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive activity), **chlorpropamide** (a first-generation sulfonylurea antidiabetic), **methotrexate** (an antimetabolite and antifolate agent used in both immune-related and neoplastic conditions), **doxorubicin** (an anthracycline antibiotic widely used as a cytotoxic chemotherapeutic agent), **streptozocin** (a nitrosourea alkylating agent used primarily in pancreatic cancer), and **hydroxyurea** (an antimetabolite chemotherapeutic and cytoreductive agent)[2][3][9][10][19]. These drugs together target multiple distinct molecular pathways: inflammation, immune modulation, DNA synthesis, and cancer cell division, and would be considered an investigational or highly experimental combination, as there is no evidence of an approved single product or fixed regimen containing all of these components together in clinical use.